Antibiotic Usage and Stewardship in Patients with COVID-19: Too Much Antibiotic in Uncharted Waters?
Overview
Affiliations
Background: Antimicrobial usage and stewardship programmes during COVID-19 have been poorly studied. Prescribing practice varies despite national guidelines, and there is concern that stewardship principles have suffered.
Aim: To analyse antibiotic prescriptions during the COVID-19 pandemic at a teaching hospital and to propose improved approaches to stewardship.
Methods: We reviewed COVID-19 admissions to medical wards and intensive care units (ICUs) in a London teaching hospital to assess initial antibiotic usage and evidence of bacterial co-infection, and to determine if our current antibiotic guidelines were adhered to.
Findings: Data from 130 inpatients (76% medical and 24% ICU) were obtained. On admission, 90% were treated with antibiotics. No microbiological samples taken on admission provided definitive evidence of respiratory co-infection. In 13% of cases, antibiotics were escalated, usually without supporting clinical, radiological or laboratory evidence. In 16% of cases, antibiotics were stopped or de-escalated within 72 h. Blood results and chest radiographs were characteristic of COVID-19 in 20% of ward patients and 42% of ICU patients. Overall mortality was 25% at 14 days - similar to rates described for the UK as a whole.
Conclusion: The majority of patients received antibiotics despite limited evidence of co-infection. Most patients received narrower spectrum antibiotics than recommended by NICE. As understanding of the natural history of COVID-19 infections progresses, stewardship programmes will need to evolve; however, at this point, we feel that a more restrictive antibiotic prescribing approach is warranted. We propose strategies for effective stewardship and estimate the effect this may have on antibiotic consumption.
Bakir Ekinci P, Kara E, Dizman G, Sonmezer M, Inkaya A, Demirkan K Turk J Pharm Sci. 2025; 21(6):489-498.
PMID: 39801000 PMC: 11730005. DOI: 10.4274/tjps.galenos.2023.44675.
Barros R, Barros C, Kegele F, Francisca da S N Soares M, de Paula G Braz J Microbiol. 2024; 55(2):1445-1449.
PMID: 38687418 PMC: 11153377. DOI: 10.1007/s42770-024-01356-4.
Khan S, Bond S, Lee-Milner J, Conway B, Lattyak W, Aldeyab M JAC Antimicrob Resist. 2024; 6(1):dlae013.
PMID: 38328263 PMC: 10848649. DOI: 10.1093/jacamr/dlae013.
Crook P, Logan C, Mazzella A, Wake R, Cusinato M, Yau T BMC Infect Dis. 2023; 23(1):808.
PMID: 37978457 PMC: 10656831. DOI: 10.1186/s12879-023-08697-9.
Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis.
Langford B, So M, Simeonova M, Leung V, Lo J, Kan T Lancet Microbe. 2023; 4(3):e179-e191.
PMID: 36736332 PMC: 9889096. DOI: 10.1016/S2666-5247(22)00355-X.